Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.P. Weetman.
Graves’ disease.
N Engl J Med, 343 (2000), pp. 1236-1248
[2.]
J.C. GalogréJ, R.V. García-Mayor, E. Fluiters, L. Fernández-Calvet, A. Rego, C. Páramo, et al.
Incidence of different forms of thyroid dysfunction and its degrees in an iodine sufficient area.
Thyroidol Clin Exp, 6 (1994), pp. 49-54
[3.]
T.H. Brix, K.O. Kyvik, K. Christensen, L. Hegedüs.
Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts.
J Clin Endocrinol Metab, 86 (2001), pp. 930-934
[4.]
J.J. Corrales, A. López, J. Ciudad, M.T. Mories, J.M. Miralles, A. Orfao.
Methimazole therapy in Graves’ disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
J Endocrinol, 155 (1997), pp. 491-500
[5.]
J.J. Corrales, A. Orfao, A. López, M.T. Mories, J.M. Miralles, J. Ciudad.
Análisis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves’ disease: relationship with disease activity.
Cytometry, 30 (1997), pp. 118-123
[6.]
D. Reinwein, G. Benker, J.H. Lazarus, W.D. Alexander.
and the European Multicenter Study Group on antithyroid drug treatment. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy.
J Clin Endocrinol Metab, 76 (1993), pp. 1516-1521
[7.]
A. Lucas, I. Salinas, F. Rius, E. Pizarro, M.L. Granada, M. Foz, et al.
Medical therapy of Graves’ disease: does thyroxine prevent recurrence of hyperthyroidism?.
J Clin Endocrinol Metab, 82 (1997), pp. 2410-2413
[8.]
P. Vitti, T. Rago, L. Chiovato, S. Pallini, F. Santini, E. Fiore, et al.
Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment.
Thyroid, 7 (1997), pp. 369-375
[9.]
O. Sabri, M. Zimny, G. Schultz, M. Schreckenberger, P. Reinartz, K. Willmes, et al.
Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication.
J Clin Endocrinol Metab, 84 (1999), pp. 1229-1233
[10.]
D. Glinoer, D. Hesch, R. Lagasse, P. Laurberg.
The management of hyperthyroidism due to Graves’ disease in Europe in 1986 Results of an international survey.
Acta Endocrinol, 115 (1987), pp. 1-23
[11.]
H. Schleusener, J. Schwander, C. Fischer, R. Holle, G. Holl, K. Badenhoop, et al.
Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease.
Acta Endocrinol, 120 (1989), pp. 689-701
[12.]
A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C.L. Gough, J.A. Franklyn.
Age and gender predict the outcome of treatment for Graves’ hyperthyroidism.
J Clin Endocrinol Metab, 85 (2000), pp. 1038-1042
[13.]
N.S. Glaser, D.M. Styne.
Predictors of early remission of hyperthyroidism in children.
J Clin Endocrinol Metab, 82 (1997), pp. 1719-1726
[14.]
A.P. Weetman, S. Ratanachaiyavong, G.W. Middleton, W. Love, R. John, G.M. Owen, et al.
Prediction of outcome in Graves’ disease after carbimazole treatment.
Quart J Med, 228 (1986), pp. 409-419
[15.]
B. Winsa, P.A. Dahlberg, R. Jansson, H. Agren, F.A. Karlsson.
Factors influencing the outcome of thyrostatic drug therapy in Graves’ disease.
Acta Endocrinol, 122 (1990), pp. 722-728
[16.]
W. Raber, E. Kmen, W. Waldhäusl, H. Vierhapper.
Medical therapy of Graves’ disease: effect on remission rates of methimazole alone and in combination with triiodothyronine.
Eur J Endocrinol, 142 (2000), pp. 117-124
[17.]
V. Michelangelli, C. Poon, J. Taft, H. Newnham, D. Topliss, P. Colman.
The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs.
Thyroid, 8 (1998), pp. 119-124
[18.]
N. Takasu, K. Yamashiro, I. Komiya, Y. Ochi, Y. Sato, A. Nagata.
Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Thyroid, 10 (2000), pp. 891-896
[19.]
S. Costagliola, N.G. Morgenthaler, R. Hoermann, K. Badenhoop, J. Struck, D. Freitag, et al.
Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease.
J Clin Endocrinol Metab, 84 (1999), pp. 90-97
[20.]
D. Maugendre, C. Massart.
Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves’ disease. Comparison with thyroid stimulating antibody bioassay.
Clin Endocrinol, 54 (2001), pp. 89-96
[21.]
C. Massart, J. Orgiazzi, D. Maugendre.
Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves’ disease treated with antithyroid drugs.
Clin Chim Acta, 304 (2001), pp. 39-47
[22.]
M. Zingrillo, L. D’Aloiso, M.R. Ghiggi, A. Di Cerbo, I. Chiodini, M. Torlontano, et al.
Thyroid hypoechogenicity after methimazole withdrawal in Graves’ disease: a useful index for predicting recurrence?.
Clin Endocrinol, 45 (1996), pp. 201-206
[23.]
K. Varsamidis, E. Varsamidou, G. Mavropoulos.
Doppler ultrasonography in predicting relapse of hyperthyroidism in Graves’ disease.
Acta Radiol, 41 (2000), pp. 45-48
[24.]
J.J. Corrales, A. López, J. Ciudad, A. Orfao.
The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves’ disease patients after methimazole therapy.
J Biol Regul Homeost Agents, 14 (2000), pp. 193-199
[25.]
K. Badenhoop, H. Donner, J. Braun, T. Siegmund, H. Rau, K.H. Usadel.
Genetic markers in diagnosis and prediction of relapse in Graves’ disease.
Exp Clin Endocrinol Diabetes, 104 (1996), pp. 98-100
[26.]
K. Hashizume, K. Ichikawa, A. Sakurai, S. Suzuki, T. Takeda, M. Kobayashi, et al.
Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
N Engl J Med, 324 (1991), pp. 947-953
[27.]
R.S. Rittmaster, E.C. Abbott, R. Douglas, M.L. Givner, L. Lehmann, S. Reddy, et al.
Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease.
J Clin Endocrinol Metab, 83 (1998), pp. 814-818
[28.]
G. Benker, D. Reinwein, G. Kahaly, L. Tegler, W.D. Alexander, J. Fassbinder, et al.
Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study.
Clin Endocrinol, 49 (1998), pp. 451-457
[29.]
H. Allannic, R. Fauchet, J. Orgiazzi, A.M. Madec, B. Genetet, Y. Lorcy, et al.
Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration.
J Clin Endocrinol Metab, 70 (1990), pp. 675-679
[30.]
D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, et al.
Antithyroid drugs and Graves’ disease-Prospective randomized assessment of long-term treatment.
Clin Endocrinol, 50 (1999), pp. 127-132
Copyright © 2002. Sociedad Española de Endocrinología y Nutrición
